Genomics of multiple myeloma

Journal of Clinical Oncology

Volumn 35, Issue 9, 2017, Pages 963-967

  Du Pont, Sebastien Robiou ^a   Cleynen, Alice ^b   Fontan, Charlotte ^a   Attal, Michel ^a   Munshi, Nikhil ^c   Corre, Jill ^a   Avet Loiseau, Hervé ^a  

^a L'Institut Universitaire du Cancer Oncopole   (France)

^b UNIV MONTPELLIER   (France)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE;

CANCER PROGNOSIS; CLONAL VARIATION; DNA SEQUENCE; GENE DOSAGE; GENE MUTATION; GENETIC PROCEDURES; GENOMICS; HUMAN; MULTIPLE MYELOMA; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; SIGNAL TRANSDUCTION; WHOLE EXOME SEQUENCING; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; PLOIDY; PROCEDURES;

GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MULTIPLE MYELOMA; MUTATION; PLOIDIES;

EID: 85016244924     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.70.6705     Document Type: Review

References (44)

1. Läi JL, Zandecki M, Mary JY, et al: Improved cytogenetics in multiple myeloma: A study of 151 patients including 117 patients at diagnosis. Blood 85:2490-2497, 1995
2. Smadja NV, Bastard C, Brigaudeau C, et al: Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98:2229-2238, 2001
3. Calasanz MJ, Cigudosa JC, Odero MD, et al: Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations. Genes Chromosomes Cancer 18:84-93, 1997
4. Nishida K, Tamura A, Nakazawa N, et al: The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 90:526-534, 1997
5. Avet-Loiseau H, Li JY, Facon T, et al: High incidence of translocations t (11;14) (q13;q32) and t (4; 14) (p16;q32) in patients with plasma cell malignancies. Cancer Res 58:5640-5645, 1998
6. Fonseca R, Debes-Marun CS, Picken EB, et al: The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 102:2562-2567, 2003
7. Drach J, Ackermann J, Fritz E, et al: Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventionaldose chemotherapy. Blood 92:802-809, 1998
8. Avet-Loiseau H, Attal M, Moreau P, et al: Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myélome. Blood 109:3489-3495, 2007
9. Bergsagel PL, Kuehl WM, Zhan F, et al: Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma. Blood 106:296-303, 2005
10. Zhan F, Hardin J, Kordsmeier B, et al: Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99:1745-1757, 2002
11. Magrangeas F, Nasser V, Avet-Loiseau H, et al: Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 101:4998-5006, 2003
12. Zhan F, Huang Y, Colla S, et al: The molecular classification of multiple myeloma. Blood 108:2020-2028, 2006
13. Broyl A, Hose D, Lokhorst H, et al: Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 116:2543-2553, 2010
14. Decaux O, Lodé L, Magrangeas F, et al: Predictionof survivalinmultiple myeloma based ongene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: A study of the Intergroupe Francophone du Myélome. J Clin Oncol 26:4798-4805, 2008
15. Carrasco DR, Tonon G, Huang Y, et al: Highresolution genomic profiles define distinct clinicopathogenetic subgroups of multiple myeloma patients. Cancer Cell 9:313-325, 2006
16. Avet-Loiseau H, Li C, Magrangeas F, et al: Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 27:4585-4590, 2009
17. Chng WJ, Kumar S, Vanwier S, et al: Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 67:2982-2989, 2007
18. Chesi M, Nardini E, Brents LA, et al: Frequent translocation t (4;14) (p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16:260-264, 1997
19. Chesi M, Nardini E, Lim RS, et al: The t (4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 92:3025-3034, 1998
20. Chesi M, Bergsagel PL, Shonukan OO, et al: Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91:4457-4463, 1998
21. Hurt EM, Wiestner A, Rosenwald A, et al: Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5:191-199, 2004
22. Hanamura I, Iida S, Akano Y, et al: Ectopic expression of MAFB gene in human myeloma cells carrying (14;20) (q32;q11) chromosomal translocations. Jpn J Cancer Res 92:638-644, 2001
23. Shaughnessy J Jr, Gabrea A, Qi Y, et al: Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 98:217-223, 2001
24. Chretien ML, Corre J, Lauwers-Cances V, et al: Understanding the role of hyperdiploidy in myeloma prognosis: Which trisomies really matter? Blood 126:2713-2719, 2015
25. Hebraud B, Leleu X, Lauwers-Cances V, et al: Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: The IFM experience on 1195 patients. Blood 28:675-679, 2014
26. Hanamura I, Stewart JP, Huang Y, et al: Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108:1724-1732, 2006
27. Lodé L, Eveillard M, Trichet V, et al: Mutations in TP53 are exclusively associated with del (17p) in multiple myeloma. Haematologica 95:1973-1976, 2010
28. Liu Y, Chen C, Xu Z, et al: Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. Nature 531:471-475, 2016
29. Palumbo A, Avet-Loiseau H, Oliva S, et al: Revised International Staging System for multiple myeloma: A report from International Myeloma Working Group. J Clin Oncol 33:2863-2869, 2015
30. Chapman MA, Lawrence MS, Keats JJ, et al: Initial genome sequencing and analysis of multiple myeloma. Nature 471:467-472, 2011
31. Bolli N, Avet-Loiseau H, Wedge DC, et al: Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 5:2997, 2014
32. Lohr JG, Stojanov P, Carter SL, et al: Widespread genetic heterogeneity in multiple myeloma: Implications for targeted therapy. Cancer Cell 25:91-101, 2014
33. Walker BA, Wardell CP, Murison A, et al: APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun 6:6997, 2015
34. Tiacci E, Trifonov V, Schiavoni G, et al: BRAF mutations in hairy-cell leukemia. N Engl J Med 364:2305-2315, 2011
35. Treon SP, Xu L, Yang G, et al: MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med 367:826-833, 2012
36. Alexandrov LB, Nik-Zainal S, Wedge DC, et al: Signatures of mutational processes in human cancer. Nature 500:415-421, 2013
37. [Erratum: Nature 502:258, 2013]
38. Walker BA, Boyle EM, Wardell CP, et al: Mutational spectrum, copy number changes, and outcome: Results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol 33:3911-3920, 2015
39. Rashid NU, Sperling AS, Bolli N, et al: Differential and limited expression of mutant alleles in multiple myeloma. Blood 124:3110-3117, 2014
40. Magrangeas F, Avet-Loiseau H, Gouraud W, et al: Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 27:473-481, 2013
41. Walker BA, Wardell CP, Melchor L, et al: Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t (4; 14) and t (11;14) myeloma. Blood 120:1077-1086, 2012
42. Morgan GJ, Walker BA, Davies FE: The genetic architecture of multiple myeloma. Nat Rev Cancer 12:335-348, 2012
43. Walker BA, Wardell CP, Melchor L, et al: Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 28:384-390, 2014
44. Andrulis M, Lehners N, Capper D, et al: Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov 3:862-869, 2013